Could fibrates (PPAR-alpha ligands) have a therapeutic potential in glioblastoma multiforme?
¿Pueden los fibratos (ligandos de PPAR-alfa) tener un potencial terapéutico en el glioblastoma multiforme?
a Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México
b Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México
c Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México
Read
4196
Timeswas read the article
1159
Total PDF
3037
Total HTML
Share statistics
array:19 [ "pii" => "X1665579613082833" "issn" => "16655796" "estado" => "S300" "fechaPublicacion" => "2013-04-01" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Medicina Universitaria. 2013;15:95-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2588 "formatos" => array:3 [ "EPUB" => 33 "HTML" => 1943 "PDF" => 612 ] ] "itemAnterior" => array:16 [ "pii" => "X1665579613082825" "issn" => "16655796" "estado" => "S300" "fechaPublicacion" => "2013-04-01" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Medicina Universitaria. 2013;15:91-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4346 "formatos" => array:3 [ "EPUB" => 50 "HTML" => 3598 "PDF" => 698 ] ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Estornudo psicógeno intratable: reporte de un caso de estornudos psicógenos desencadenados por <span class="elsevierStyleItalic">bullying</span> escolar" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "91" "paginaFinal" => "94" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Untreatable psychogenic sneezing: report of one case of psychogenic sneezing due to school bullying" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alejandro Durán-De la Re, Beatriz Chávez-Luévanos, Adriana Carlota Cantú-Salinas, Cristina Elizabeth García-Guerrero, Ezequiel Enrique Paypa-Jabre" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Durán-De la Re" ] 1 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Chávez-Luévanos" ] 2 => array:2 [ "nombre" => "Adriana Carlota" "apellidos" => "Cantú-Salinas" ] 3 => array:2 [ "nombre" => "Cristina Elizabeth" "apellidos" => "García-Guerrero" ] 4 => array:2 [ "nombre" => "Ezequiel Enrique" "apellidos" => "Paypa-Jabre" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1665579613082825?idApp=UINPBA00004N" "url" => "/16655796/0000001500000059/v0_201307311013/X1665579613082825/v0_201307311015/es/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "titulo" => "Could fibrates (PPAR-alpha ligands) have a therapeutic potential in glioblastoma multiforme?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "95" "paginaFinal" => "98" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Carlos Rodrigo Cámara-Lemarroy, René Rodríguez-Gutiérrez, Miguel A. Villarreal-Alarcón" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Carlos Rodrigo" "apellidos" => "Cámara-Lemarroy" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "René" "apellidos" => "Rodríguez-Gutiérrez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Miguel A." "apellidos" => "Villarreal-Alarcón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Department of Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, N.L., México " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Pueden los fibratos (ligandos de PPAR-alfa) tener un potencial terapéutico en el glioblastoma multiforme?" ] ] "textoCompleto" => "<p class="elsevierStylePara"> </p> Pagina nueva 4 <p class="elsevierStylePara"><span class="elsevierStyleBold">Introduction</span></p><p class="elsevierStylePara"> Gliomas are the most common type of primary brain tumors, deriving from astrocytes, oligodendrocytes and ependymal cells. They are divided in four grades, grade 4 being the highest grade, where glioblastoma multiforme (GBM), the most common type of glioma, is the main representative. It is one of the most malignant primary brain tumors, with dismal survival rates in the short term, and despite of decades of research and surgical developments, therapy has notably failed to alter prognosis significantly.<span class="elsevierStyleSup">1,2</span></p><p class="elsevierStylePara"> Peroxisome proliferator-activated receptors (PPARs), discovered in rodents in 1990, are proteins that belong to the superfamily of the nuclear hormone factor re- ceptor. They are similar in structure to thyroid, estrogen, retinoic acid and glucocorticoid receptors. This structure include the amino-terminal activation function-1 trans activation domain, a DNA-binding domain, and a ligand-binding domain in the carboxy-terminal region.<span class="elsevierStyleSup">3</span> PPARs exist in three subtypes; alpha, beta/delta and gamma. PPAR-alpha is highly expressed in hepatocytes, cardiomyocytes, enterocytes, and the proximal tubule cells of kidney. PPAR-beta is expressed ubiquitously and often at higher levels than PPAR-alpha and -gamma. On the other hand, PPAR-gamma is expressed predominantly in adipose tissue and also in the immune system. They all mediate the physiological actions of fatty acids and fatty acid derived molecules, and their natural activating ligands are themselves lipid-derived substrates. Their activation regulates gene transcription, modulation of additional transcription factors and DNA responses that aim at maintaining lipid and glucose homeostasis.<span class="elsevierStyleSup">3,4</span> They mediate lipid metabolism, cell growth, and have demonstrated pleiotropic effects over the immune system and other pathways.<span class="elsevierStyleSup">4,5</span></p><p class="elsevierStylePara"> The modulation of PPARs using various drugs has proven clinically useful in the treatment of diabetes (PPAR-gamma agonists, such as pioglitazone) and dyslipidemia (PPAR-alpha agonists, such as fibrates). PPAR-alpha in particular is known to modulate the activities of fatty acid oxidation systems, to modulate the transcription of cytokine genes, to alter the cell growth cycle, change the expression profiles of lymphocytes, among many other pleiotropic effects.<span class="elsevierStyleSup">6</span> The presence of PPAR-alpha receptors in glioblastoma cell lines has been demonstrated, and these are implicated in brain development, neural cell differentiation and lipid metabolism in the brain. The hypothesis here advanced is that PPAR-alpha activators, such as fibrates, have anti-tumor activity against GBM.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PPAR-gamma</span></p><p class="elsevierStylePara"> PPARs are ubiquitous in GBM cell lines, and there is plenty of evidence, experimental and even clinical, that PPAR-gamma agonists (thiazolidinediones), have anti-tumor effects over GBM.<span class="elsevierStyleSup">7</span> Indeed, a recent phase II study showed that low dose combination of pioglitazone, rofecoxib and chemotherapy, is moderately active and well tolerated regimen in patients with high-grade gliomas.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara"> However, comparatively few information exists on PPAR-alpha agonists.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PPAR-alpha</span></p><p class="elsevierStylePara"> Traditionally, PPAR-alpha activation has been linked to the carcinogenesis, and specifically, development of liver tumors.<span class="elsevierStyleSup">9</span> However, anti-tumor effects of PPAR-alpha have also been described. Selective ligands for PPAR-alpha exert protective role against mouse skin tumor promotion.<span class="elsevierStyleSup">10</span> It has also been shown that PPAR-alpha is up-regulated in endometrial cancer, and a PPAR-alpha-activating ligand reduces the proliferation of endometrial cancer cells.<span class="elsevierStyleSup">11</span> Similar results have been obtained in ovarian cancer cells.<span class="elsevierStyleSup">12</span> Recent evidence points towards general anti-tumor effects of PPAR-alpha, and indeed, recent research has studied these effects over glioma cell lines.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">GBM cell anti-tumor activity of PPAR-alpha and PPAR-alpha agonists</span></p><p class="elsevierStylePara"> In an <span class="elsevierStyleItalic">in vitro</span> study, Pineau et al. showed that phenylacetate, an aromatic fatty acid anti-tumor agent, could enhance PPAR-alpha in glioblastoma cell lines in a direct proportion to its cell stasis activity, suggesting a role for PPAR-alpha in tumor cell growth.<span class="elsevierStyleSup">13</span> The induction of PPAR-alpha by linoleic acid has been shown to lead to the induction of apoptosis in tumor cell lines, suggesting a possible mechanism of action for this effect.<span class="elsevierStyleSup">14</span> The presence of PPAR-alpha in human GB cell lines has not only been confirmed, but the incubation of these cells in fenofibrate, a PPAR-alpha agonist, leads to the inhibition of cell proliferation and elevated apoptosis, through the attenuation of insulin-like growth factor-I (IGF-I) dependent phosphorylation of kinases involved in cell growth.<span class="elsevierStyleSup">15</span></p><p class="elsevierStylePara"> Further studies showed that PPAR-alpha induction indeed inhibited IGF-I, a contributing factor in supporting malignant growth and invasion of glioma cells, and led to accumulation of reactive oxygen species inside tumor cells, which in turn caused mitochondrial dysfunction and apoptosis.<span class="elsevierStyleSup">16</span> These alterations impaired GB cell motility. Also, a recent study performed on human glioblastoma cell lines U-87 MG, T98G, A172 and U-118 MG showed that ligands of PPAR alpha (bezafibrate, gemfibrozil) negatively affected the viability, proliferation, differentiation and expression of cell cycle related proteins, and led to increased apoptosis.<span class="elsevierStyleSup">17</span> Finally, a recent <span class="elsevierStyleItalic">in vitro </span>study showed that TZD18 a novel PPAR alfa/gamma dual agonist inhibited cell grow and induced apoptosis in human glioblastoma T98G cells reinforcing the possibility that in an <span class="elsevierStyleItalic">in vivo</span> study this could be replicated.18</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Other possible mechanisms</span></p><p class="elsevierStylePara"> Cyclooxygenase (COX)-2 and vascular endothelial growth factor (VEGF) are crucial agents in inflammatory and angiogenic processes. Both have been implicated in tumor progression and both are modulated by PPAR-alpha.<span class="elsevierStyleSup">19</span></p><p class="elsevierStylePara"> PPAR-alpha agonists can inhibit VEGF and suppress endothelial cell proliferation, resulting in potent antiangogenic effects.<span class="elsevierStyleSup">20</span> VEGF not only is known to be crucial in GBM angiogenesis and progression, but currently, anti-VEGF therapy is the standard of care in GBM chemotherapy.<span class="elsevierStyleSup">21</span> PPAR-alpha activators have also been shown to inhibit the tumor necrosis factor-alpha/Nuclear factor KappaB (TNF-alpha/Nf-KappaB) axis in mantle cell lymphoma, a transcription pathway of various cytokine and inflammation genes.<span class="elsevierStyleSup">22</span> The TNF-alpha/Nf-KappaB signaling pathways is thought to drive the tumor phenotype and participate in GBM pathogenesis as well,<span class="elsevierStyleSup">23</span> and there is direct evidence of Nf-KappaB modulation in cultured microglia by fenofibrate.<span class="elsevierStyleSup">24</span> These pleiotropic effects could be relevant for the anti-tumor effects of fibrates.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conclusion</span></p><p class="elsevierStylePara"> Fibrates (fenofibrate, clofibrate, bezafibrate, ciprofibrate) are commonly used, safe and well tolerated drugs. Their current approved indication lies mainly in the realm of management of dyslipidemia, and they are effective in reducing triglyceride and cholesterol levels. In combination with a HMG-CoA inhibitor (statins), they constitute the most effective lipid lowering pharmacological strategy. Fibrates and statins act synergistically. Interestingly, statins have also shown potential in the treatment of GBM. The combination of lovastatin and troglitazone was shown to synergistically inhibit GB cell line growth.<span class="elsevierStyleSup">25</span></p><p class="elsevierStylePara"> Considering the information reviewed in this article, the use of fibrates, in combination with currently approved chemotherapy regimens, in human clinical trials, holds great promise.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara"> The authors declare no conflict of interest.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Financial support</span></p><p class="elsevierStylePara"> None.</p><hr></hr><p class="elsevierStylePara"><span class="elsevierStyleItalic">Correspondence:</span><br></br> Carlos Rodrigo Cámara Lemarroy, MD. <br></br> Department of Internal Medicine, <span class="elsevierStyleItalic">Hospital Universitario "Dr. José Eleuterio González". </span><br></br> Av. Francisco I. Madero y Dr. Eduardo Aguirre Pequeño s/n, colonia Mitras Centro, Z.P. <br></br> 64460, Monterrey, N.L., México. Telephone/Fax: (+52 81) 8329 4203. <span class="elsevierStyleItalic"><br></br> E-mail</span>: <a href="mailto:crcamara83@hotmail.com" class="elsevierStyleCrossRefs">crcamara83@hotmail.com</a></p><p class="elsevierStylePara"> Received: October 2012. <br></br> Accepted: March 2013</p>" "pdfFichero" => "304v15n59a90208283pdf001.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec226716" "palabras" => array:1 [ 0 => "Receptor activado por proliferador de peroxisomas alfa (PPAR-alfa), glioblastoma multiforme, tumor cerebral, fibratos, México" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec226717" "palabras" => array:1 [ 0 => "Peroxisome proliferator-activated receptor-alpha, glioblastoma multiforme, cerebral tumor, fibrates, Mexico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara"> Los gliomas son los tumores cerebrales primarios más frecuentes. Son divididos en cuatro grados, siendo el cuarto grado el más agresivo, en donde el glioblastoma multiforme (GBM) es el representante principal. Es uno de los tumores primarios malignos de cerebro más agresivos; a pesar de décadas de estudios de investigación y de avances en técnicas quirúrgicas, el tratamiento actual ha fallado en mejorar el pronóstico de manera significativa. Por lo tanto, existe una necesidad de nuevos tratamientos para el GBM. Los receptores de los peroxisomas-proliferador-activado alfa (PPAR-alfa), han demostrado modular múltiples vías inflamatorias, metabólicas y de crecimiento celular, existiendo la evidencia experimental, que indica que pudiera tener también propiedades antineoplásicas. Evidencia experimental reciente sugiere que las líneas celulares del GBM, utilizan PPAR-alfa para controlar su crecimiento. Adicionalmente, es ya bien reconocido que las células del GBM utilizan factores de adhesión, citocinas proinflamatorias y estrés oxidativo como mecanismos patofisiológicos de diferenciación e invasión. Los ligandos de PPAR-alfa, han demostrado ya en múltiples estudios experimentales in vivo e in vitro, que pueden inhibir estos mediadores. Esto sugiere un potencial uso de los ligandos de PPAR-alfa en el tratamiento del GBM. Los fibratos, tal como el fenofibrato, son medicamentos comúnmente utilizados para el tratamiento de dislipidemias y su mecanismo de acción es precisamente como ligandos de PPAR-alfa. En este trabajo proponemos el uso en estudios clínicos, de los fibratos como terapia adyuvante en el tratamiento de GBM.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara"> Gliomas are the most common type of primary brain tumors. They are divided in four grades, grade 4 being the highest grade, where glioblastoma multiforme (GBM) is the main representative. It is one of the most malignant primary brain tumors, and despite of decades of research and surgical developments, therapy has notably failed to alter prognosis significantly. There is an increasing need for novel therapies in the treatment of GBM. Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is known to modulate multiple inflammatory, metabolic and cell growth pathways, and there is experimental evidence that it has some antineoplastic properties. Recent experimental evidence suggests that GBM cell lines use PPAR-alpha signaling in controlling their growth. Additionally, it is known that GBM cells use cell adhesion factors, pro-inflammatory cytokines and oxidative stress as pathophysiological mechanisms of differentiation and invasion. PPAR-alpha has been shown to inhibit these mediators in multiple<span class="elsevierStyleItalic"> in vivo</span> and <span class="elsevierStyleItalic">in vitro</span> experimental models. This suggests a potential use for PPAR-alpha ligands in the treatment of GBM, a possibility not yet fully explored. Fibrates, such as fenofibrate, are drugs commonly prescribed in the management of dyslipidemia, and they are known to act as ligands for PPAR-alpha. In this paper we propose the use of fibrates in the adjuvant management of GBM in human clinical trials.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:25 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Primary Brain Tumors in Adults." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Sreenivasa RC" 1 => "Sujana M" 2 => "Madan A" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Am Fam Physician 2008" "volumen" => "77" "paginaInicial" => "1423" "paginaFinal" => "1430" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Brain tumours: classifi cation and genes." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Collins VP." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "fecha" => "J Neurol Neurosurg Psychiatry 2004" "volumen" => "75" "paginaInicial" => "Suppl 2" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Tyagi S" 1 => "Gupta P" 2 => "Saini AS" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "J Adv Pharm Technol Res 2011" "volumen" => "2" "paginaInicial" => "236" "paginaFinal" => "240" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Involvement of PPAR nuclear receptors in tissue injury and wound repair." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Michalik L" 1 => "Wahli W." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "J Clin Invest 2006" "volumen" => "116" "paginaInicial" => "598" "paginaFinal" => "606" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PPAR and immune system-what do we know? Int Immunopharmacol 2002." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Zhang X" 1 => "Young HA." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "volumen" => "2" "paginaInicial" => "1029" "paginaFinal" => "1044" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PPARα." "idioma" => "el" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Pyper SR" 1 => "Viswakarma N" 2 => "Yu S" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Peroxisome Proliferator-Activated Receptor Pathway Targeting in Carcinogenesis: Implications for Chemoprevention." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ondrey F." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Clin Cancer Res 2009" "volumen" => "15" "paginaInicial" => "2" "paginaFinal" => "8" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Hau P" 1 => "Kunz-Schughart L" 2 => "Bogdahn U" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Oncology 2007" "volumen" => "73" "paginaInicial" => "21" "paginaFinal" => "25" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Gonzalez FJ" 1 => "Shah YM." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Toxicology 2008" "volumen" => "246" "paginaInicial" => "2" "paginaFinal" => "8" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Activators of peroxisome proliferator- activated receptor-a partially inhibit mouse skin tumor promotion." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Thuillier P" 1 => "Anchiraico GJ" 2 => "Nickel KP" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "fecha" => "Mol Carcinog 2000" "volumen" => "29" "paginaInicial" => "134" "paginaFinal" => "142" "itemHostRev" => array:3 [ "pii" => "S0140673688921721" "estado" => "S350" "issn" => "01406736" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Transcriptional analysis ofendometrial cancer identifies peroxisome proliferator activated receptors as potential therapeutic targets." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Holland CM" 1 => "Saidi SA" 2 => "Evans AL" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Mol Cancer Ther 2004" "volumen" => "3" "paginaInicial" => "993" "paginaFinal" => "1001" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Clofibric acid, a peroxisome proliferator-activated receptor A ligand, inhibits growth of human ovarian cancer." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Yokoyama Y" 1 => "Xin B" 2 => "Shigeto T" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Mol Cancer Ther 2007" "volumen" => "6" "paginaInicial" => "1379" "paginaFinal" => "1386" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Pineau T" 1 => "Hudgins WR" 2 => "Liu L" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Biochem Pharmacol 1996" "volumen" => "23" "paginaInicial" => "659" "paginaFinal" => "567" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Maggiora M" 1 => "Bologna M" 2 => "Cerù MP" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Int J Cancer 2004" "volumen" => "112" "paginaInicial" => "909" "paginaFinal" => "919" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Urbanska K" 1 => "Pannizzo P" 2 => "Grabacka M" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Int J Cancer 2008" "volumen" => "123" "paginaInicial" => "1015" "paginaFinal" => "1024" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Drukala J" 1 => "Urbanska K" 2 => "Wilk A" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Strakova N" 1 => "Ehrmann J" 2 => "Bartos J" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Neoplasma 2005" "volumen" => "52" "paginaInicial" => "126" "paginaFinal" => "136" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Lui DC" 1 => "Zang CB" 2 => "Lui HY" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Acta Pharmacol Sin 2004" "volumen" => "25" "paginaInicial" => "1312" "paginaFinal" => "1319" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Grau R" 1 => "Díaz-Muñoz MD" 2 => "Cacheiro-Llaguno C" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "PPAR Res 2008" "volumen" => "2008" "paginaInicial" => "352437" "itemHostRev" => array:3 [ "pii" => "S0140673600022121" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Panigrahy D" 1 => "Kaipainen A" 2 => "Huang S" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Proc Natl Acad Sci U S A 2008" "volumen" => "105" "paginaInicial" => "985" "paginaFinal" => "990" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Antiangiogenic therapies for high-grade glioma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Norden AD" 1 => "Drappatz J" 2 => "Wen PY." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Nat Rev Neurol 2009" "volumen" => "5" "paginaInicial" => "610" "paginaFinal" => "620" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/ NF-kappaB signaling axis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Zak Z" 1 => "Gelebart P" 2 => "Lai R." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Leukemia 2010" "volumen" => "24" "paginaInicial" => "1476" "paginaFinal" => "1486" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "NF-kappaB and STAT3 signaling in glioma: targets for future therapies." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Atkinson GP" 1 => "Nozell SE" 2 => "Benveniste ET." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Expert Rev Neurother 2010" "volumen" => "10" "paginaInicial" => "575" "paginaFinal" => "586" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Ramanan S" 1 => "Kooshki M" 2 => "Zhao W" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Free Radic Biol Med 2008" "volumen" => "45" "paginaInicial" => "1695" "paginaFinal" => "1704" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Yao CJ" 1 => "Lai GM" 2 => "Chan CF" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "Int J Cancer 2006" "volumen" => "118" "paginaInicial" => "773" "paginaFinal" => "779" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16655796/0000001500000059/v0_201307311013/X1665579613082833/v0_201307311015/en/main.assets" "Apartado" => array:4 [ "identificador" => "13663" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Artículos de revisión" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/16655796/0000001500000059/v0_201307311013/X1665579613082833/v0_201307311015/en/304v15n59a90208283pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1665579613082833?idApp=UINPBA00004N" ]
Article information
ISSN: 16655796Original language: English
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 October | 7 | 4 | 11 |
| 2024 September | 25 | 5 | 30 |
| 2024 August | 26 | 6 | 32 |
| 2024 July | 17 | 7 | 24 |
| 2024 June | 14 | 2 | 16 |
| 2024 May | 17 | 2 | 19 |
| 2024 April | 18 | 4 | 22 |
| 2024 March | 20 | 7 | 27 |
| 2024 February | 9 | 6 | 15 |
| 2024 January | 63 | 7 | 70 |
| 2023 December | 9 | 10 | 19 |
| 2023 November | 8 | 5 | 13 |
| 2023 October | 23 | 14 | 37 |
| 2023 September | 10 | 5 | 15 |
| 2023 August | 19 | 5 | 24 |
| 2023 July | 20 | 6 | 26 |
| 2023 June | 13 | 1 | 14 |
| 2023 May | 34 | 11 | 45 |
| 2023 April | 23 | 0 | 23 |
| 2023 March | 29 | 5 | 34 |
| 2023 February | 24 | 6 | 30 |
| 2023 January | 22 | 6 | 28 |
| 2022 December | 15 | 8 | 23 |
| 2022 November | 16 | 8 | 24 |
| 2022 October | 12 | 8 | 20 |
| 2022 September | 16 | 14 | 30 |
| 2022 August | 16 | 22 | 38 |
| 2022 July | 18 | 8 | 26 |
| 2022 June | 10 | 9 | 19 |
| 2022 May | 17 | 4 | 21 |
| 2022 April | 15 | 17 | 32 |
| 2022 March | 11 | 7 | 18 |
| 2022 February | 10 | 6 | 16 |
| 2022 January | 30 | 5 | 35 |
| 2021 December | 19 | 14 | 33 |
| 2021 November | 24 | 12 | 36 |
| 2021 October | 42 | 9 | 51 |
| 2021 September | 28 | 12 | 40 |
| 2021 August | 18 | 6 | 24 |
| 2021 July | 21 | 4 | 25 |
| 2021 June | 16 | 3 | 19 |
| 2021 May | 21 | 8 | 29 |
| 2021 April | 39 | 24 | 63 |
| 2021 March | 26 | 5 | 31 |
| 2021 February | 14 | 13 | 27 |
| 2021 January | 31 | 17 | 48 |
| 2020 December | 13 | 19 | 32 |
| 2020 November | 11 | 27 | 38 |
| 2020 October | 8 | 22 | 30 |
| 2020 September | 12 | 11 | 23 |
| 2020 August | 18 | 15 | 33 |
| 2020 July | 17 | 8 | 25 |
| 2020 June | 15 | 11 | 26 |
| 2020 May | 18 | 23 | 41 |
| 2020 April | 19 | 22 | 41 |
| 2020 March | 21 | 14 | 35 |
| 2020 February | 18 | 16 | 34 |
| 2020 January | 19 | 5 | 24 |
| 2019 December | 25 | 13 | 38 |
| 2019 November | 17 | 3 | 20 |
| 2019 October | 15 | 4 | 19 |
| 2019 September | 23 | 3 | 26 |
| 2019 August | 4 | 5 | 9 |
| 2019 July | 22 | 13 | 35 |
| 2019 June | 27 | 23 | 50 |
| 2019 May | 58 | 52 | 110 |
| 2019 April | 33 | 13 | 46 |
| 2019 March | 10 | 2 | 12 |
| 2019 February | 7 | 5 | 12 |
| 2019 January | 6 | 0 | 6 |
| 2018 December | 8 | 1 | 9 |
| 2018 November | 7 | 4 | 11 |
| 2018 October | 12 | 8 | 20 |
| 2018 September | 9 | 6 | 15 |
| 2018 August | 4 | 1 | 5 |
| 2018 July | 10 | 3 | 13 |
| 2018 June | 7 | 0 | 7 |
| 2018 May | 9 | 7 | 16 |
| 2018 April | 9 | 2 | 11 |
| 2018 March | 10 | 1 | 11 |
| 2018 February | 3 | 1 | 4 |
| 2018 January | 7 | 1 | 8 |
| 2017 December | 10 | 0 | 10 |
| 2017 November | 8 | 4 | 12 |
| 2017 October | 7 | 1 | 8 |
| 2017 September | 12 | 1 | 13 |
| 2017 August | 11 | 0 | 11 |
| 2017 July | 11 | 1 | 12 |
| 2017 June | 19 | 5 | 24 |
| 2017 May | 30 | 2 | 32 |
| 2017 April | 18 | 6 | 24 |
| 2017 March | 11 | 33 | 44 |
| 2017 February | 5 | 3 | 8 |
| 2017 January | 15 | 1 | 16 |
| 2016 December | 18 | 0 | 18 |
| 2016 November | 19 | 2 | 21 |
| 2016 October | 15 | 1 | 16 |
| 2016 September | 9 | 1 | 10 |
| 2016 August | 11 | 0 | 11 |
| 2016 July | 12 | 4 | 16 |
| 2016 June | 35 | 9 | 44 |
| 2016 May | 32 | 15 | 47 |
| 2016 April | 28 | 14 | 42 |
| 2016 March | 37 | 12 | 49 |
| 2016 February | 32 | 15 | 47 |
| 2016 January | 21 | 18 | 39 |
| 2015 December | 35 | 14 | 49 |
| 2015 November | 33 | 15 | 48 |
| 2015 October | 32 | 16 | 48 |
| 2015 September | 21 | 10 | 31 |
| 2015 August | 43 | 4 | 47 |
| 2015 July | 34 | 3 | 37 |
| 2015 June | 21 | 3 | 24 |
| 2015 May | 23 | 7 | 30 |
| 2015 April | 26 | 10 | 36 |
| 2015 March | 25 | 9 | 34 |
| 2015 February | 15 | 3 | 18 |
| 2015 January | 28 | 1 | 29 |
| 2014 December | 43 | 12 | 55 |
| 2014 November | 16 | 4 | 20 |
| 2014 October | 35 | 9 | 44 |
| 2014 September | 44 | 4 | 48 |
| 2014 August | 44 | 6 | 50 |
| 2014 July | 40 | 7 | 47 |
| 2014 June | 42 | 1 | 43 |
| 2014 May | 27 | 4 | 31 |
| 2014 April | 27 | 0 | 27 |
| 2014 March | 50 | 9 | 59 |
| 2014 February | 57 | 10 | 67 |
| 2014 January | 49 | 9 | 58 |
| 2013 December | 49 | 14 | 63 |
| 2013 November | 45 | 22 | 67 |
| 2013 October | 73 | 21 | 94 |
| 2013 September | 68 | 19 | 87 |
| 2013 August | 60 | 21 | 81 |
| 2013 July | 34 | 13 | 47 |
| 2013 March | 6 | 0 | 6 |
Show all